Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)
Oral Intradialytic Amino Acids Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Subrata Debnath, PhD
- Phone Number: 210-567-4700
- Email: nath@uthscsa.edu
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- The University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or Female
- Age 18-64 years
- Receiving 3 x weekly in clinic hemodialysis for at least 6 months
Exclusion Criteria:
- Hypersensitivity to amino acid(s) and/or any excipient
- Clinical documentation of COVID-19
- Concomitant intake of amino acids supplements
- Current use or abuse of alcohol, marijuana, narcotic, or other substances
- Heart failure receiving active management
- Malignant cancer receiving anticancer therapy
- Diagnosis of major depressive disorder receiving antidepressants
- Diagnosis of chronic liver disease
- Cerebrovascular disease with sequelae
- Upper limb amputation, osteoarthritis, or degenerative diseases of fingers, carpel tunnel syndrome in the non-fistula or graft hand preventing completion of hand grip strength test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group Valine then EEA
Valine will be administered as two 4 gm packets administered on dialysis treatment day followed by a washout period and then EEA
|
A medical food intended for use under medical supervision
Other Names:
A medical food intended for use under medical supervision
Other Names:
|
|
Experimental: Treatment group EEA then Valine
EAA will be administered as one 12.5 gm packet administered on dialysis treatment day followed by a washout and then Valine
|
A medical food intended for use under medical supervision
Other Names:
A medical food intended for use under medical supervision
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Fatigue Inventory (BFI) score
Time Frame: Baseline to 17 weeks
|
Changes in global fatigue score measured with the 9-item Brief Fatigue Inventory (BFI).
The first 3 questions assess fatigue severity, and the remaining 6 questions measure the impact of fatigue on activity, mood, walking, work, relationships, and enjoyment of life.
Respondents rate each item on a 0-10 numeric scale, with 0 meaning "no fatigue" and 10 meaning "fatigue as bad as you can imagine."
Scores of all 9 items yield global fatigue burden.
A lower average global fatigue score indicates milder fatigue and a higher score severe fatigue.
|
Baseline to 17 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Handgrip strength test
Time Frame: Baseline to 17 weeks
|
Change in handgrip strength measured by a dynamometer in lbs
|
Baseline to 17 weeks
|
|
Trail Making Test (TMT)
Time Frame: Baseline to 17 weeks
|
Change in minutes to complete Trail Making Test (TMT) A and B
|
Baseline to 17 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dialysate level of amino acids
Time Frame: Baseline to 17 weeks
|
How is this measured, are there different values for different aa's (if so each one should be reported separately)?
|
Baseline to 17 weeks
|
|
Plasma level of amino acids
Time Frame: Baseline to 17 weeks
|
How is this measured, are there different values for different aa's (if so each one should be reported separately)?
|
Baseline to 17 weeks
|
|
Blood valine metabolite 3-hydroxyisobutyrate (3-HIB)
Time Frame: Baseline to 17 weeks
|
Change in 3-hydroxyisobutyrate (3-HIB) levels
|
Baseline to 17 weeks
|
|
Blood valine beta-amino-isobutyric acid (BAIBA)
Time Frame: Baseline to 17 weeks
|
Change in beta-amino-isobutyric acid (BAIBA)
|
Baseline to 17 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Subrata Debnath, PhD, The University of Texas Health Science Center at San Antonio
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Fatigue
- Kidney Failure, Chronic
- Amino Acids, Peptides, and Proteins
- Amino Acids
- Amino Acids, Essential
- Amino Acids, Branched-Chain
- Valine
Other Study ID Numbers
Other Study ID Numbers
- HSC20220558H
- KL2TR002646 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.